Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204584 | 0.87 | NISCH (0.54) | NISCHPRMT1 | |
| SCHEMBL1502455 | 0.85 | NISCH (0.49) | NISCHPRMT1 | |
| SCHEMBL8677423 | 0.84 | NISCH (0.50) | NISCHPRMT1 | |
| SCHEMBL549218 | 0.84 | TOP2A (0.56) | NISCHPRMT1 | |
| SCHEMBL548343 | 0.84 | NISCH (0.50) | NISCHPRMT1 | |
| SCHEMBL14599548 | 0.83 | PRMT1 (0.49) | NISCHPRMT1 | |
| SCHEMBL14599545 | 0.82 | NISCH (0.48) | NISCHPRMT1 | |
| SCHEMBL8477890 | 0.81 | NPC1 (0.58) | NISCHPRMT1 | |
| SCHEMBL8477719 | 0.80 | NISCH (0.55) | NISCHPRMT1 | |
| SCHEMBL23775778 | 0.80 | PRMT1 (0.44) | NISCHPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| EP-0973750-B1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | UNIV NORTH CAROLINA (US) | 2004-04-21 | — | — | EP | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-0973750-A1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | The University of North Carolina at Chapel Hill (US) | 2000-01-26 | — | — | EP | claimed |
| US-5817687-A | LEUKEMIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-10-06 | — | — | US | claimed |
| WO-1998038170-A1 | SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR TREATING RETROVIRAL INFECTION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-03 | — | — | WO | claimed |
| US-5792782-A | TREATING CRYPTOCOCCUS NEOFORMANS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-08-11 | — | — | US | claimed |
| EP-0831832-A1 | METHODS OF COMBATTING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-04-01 | — | — | EP | claimed |
| US-5643935-A | CRYPTOCOCCUS INFECTIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-07-01 | — | — | US | claimed |
| US-5639755-A | THERAPY FOR CRYPTOCOCCUS AND CANDIDA INFECTIONS | UNIVERSITY OF NORTH CAROLINA (US) | 1997-06-17 | — | — | US | claimed |
| WO-1996040997-A1 | METHOD OF FLUORESCENT DETECTION OF NUCLEIC ACIDS AND CYTOSKELETON ELEMENTS USING BIS-DICATIONIC ARYL FURANS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040145-A1 | METHODS OF COMBATTING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | NISCH 967/4885PRMT1 2728/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | NISCH 284/4885PRMT1 2584/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | NISCH 802/4885PRMT1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.